Thyroid carcinoma.

[1]  K. Rosenzweig,et al.  Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. , 2005, International journal of radiation oncology, biology, physics.

[2]  J. Quivey,et al.  Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival , 2001, Cancer.

[3]  D. Johnston,et al.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. , 1992, The Journal of clinical endocrinology and metabolism.

[4]  A. Oberg,et al.  Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.

[5]  R. Buchert,et al.  Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial. , 1999, Cancer biotherapy & radiopharmaceuticals.

[6]  A. Pinchera,et al.  Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.

[7]  H. Sack,et al.  Differentiated thyroid cancer: Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4) , 1996, Cancer.

[8]  M. Pelizzo,et al.  A multimodality therapeutic approach in anaplastic thyroid carcinoma: Study on 39 patients , 2000, Journal of endocrinological investigation.

[9]  E. Baudin,et al.  Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[10]  R. Leeper,et al.  Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy , 1987, Cancer.

[11]  R. Tsang,et al.  Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. , 1996, Thyroid : official journal of the American Thyroid Association.

[12]  Jiachao Liang,et al.  Phase II trial of sorafenib in metastatic thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Staunton.  Thyroid cancer: a multivariate analysis on influence of treatment on long-term survival. , 1994, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  R. Tuttle,et al.  Papillary thyroid cancer: monitoring and therapy. , 2007, Endocrinology and metabolism clinics of North America.

[15]  A. Muzikansky,et al.  The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma , 2002, Annals of Surgical Oncology.

[16]  P. Chappuis,et al.  Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. , 2001, The Journal of clinical endocrinology and metabolism.

[17]  N. Tsang,et al.  Results of external beam radiotherapy in patients with well differentiated thyroid carcinoma. , 1997, Japanese journal of clinical oncology.

[18]  W. Taylor,et al.  Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. , 1987, Surgery.

[19]  A. Schneider,et al.  Long-term risks for thyroid cancer and other neoplasms after exposure to radiation , 2005, Nature Clinical Practice Endocrinology &Metabolism.

[20]  C. Richards,et al.  Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. , 1996, The Journal of clinical endocrinology and metabolism.

[21]  N. Willich,et al.  Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer , 2009, Nuklearmedizin.

[22]  H. Holzhausen,et al.  Skip metastases in thyroid cancer leaping the central lymph node compartment. , 2004, Archives of surgery.

[23]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[24]  R. Golouh,et al.  Effect of primary treatment on survival in anaplastic thyroid carcinoma. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[25]  T. Seyama,et al.  Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. , 1992, Cancer research.

[26]  W. Hicks,et al.  Anaplastic carcinoma of the thyroid: A 24‐year experience , 1995, Head & neck.

[27]  M. Alevizaki,et al.  Iodine 131 treatment for differentiated thyroid carcinoma in patients with end stage renal failure: dosimetric, radiation safety, and practical considerations. , 2006, Hormones.

[28]  W. Simpson,et al.  The role of external radiation in the management of papillary and follicular thyroid cancer. , 1978, American journal of surgery.

[29]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[30]  D. Dearnaley,et al.  Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I study. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  W. Mendenhall,et al.  Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. , 2002, International journal of radiation oncology, biology, physics.

[32]  M. Zelefsky,et al.  Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience. , 2009, International journal of radiation oncology, biology, physics.

[33]  E. Bergstralh,et al.  Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. , 1993, Surgery.

[34]  V S Hertzberg,et al.  Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  A. Toniato,et al.  Locally advanced differentiated thyroid carcinoma: a 35-year mono-institutional experience in 280 patients , 2005, Nuclear medicine communications.

[36]  A. Garden,et al.  Postoperative radiotherapy for advanced medullary thyroid cancer—Local disease control in the modern era , 2008, Head & neck.

[37]  E. Kaplan,et al.  Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.

[38]  M. Bäckdahl,et al.  Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid cancer. , 1992, Surgery.

[39]  E. Baudin,et al.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.

[40]  W. Simpson.  Anaplastic thyroid carcinoma: a new approach. , 1980, Canadian journal of surgery. Journal canadien de chirurgie.

[41]  B. Dickson,et al.  Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once‐ and twice‐daily fractionation regimens , 2006, Cancer.

[42]  W. Simpson,et al.  Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[43]  K. D. Williams,et al.  Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. , 2007, Thyroid : official journal of the American Thyroid Association.

[44]  C. Ko,et al.  Extent of Surgery Affects Survival for Papillary Thyroid Cancer , 2007, Annals of surgery.

[45]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[46]  M. Schlumberger,et al.  External radiotherapy in thyroid cancers , 1985, Cancer.

[47]  E. Bergstralh,et al.  Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? , 1998, Surgery.

[48]  L. Grimelius,et al.  Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery , 2002, British Journal of Cancer.

[49]  A. Fard-Esfahani,et al.  Radioiodine treatment complications to the mother and child in patients with differentiated thyroid carcinoma. , 2009, Hellenic journal of nuclear medicine.

[50]  W. Beierwaltes,et al.  Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. , 1976, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[51]  R. A’Hern,et al.  Results of external beam radiotherapy in differentiated thyroid carcinoma: a retrospective study from the Royal Marsden Hospital. , 1994, European journal of cancer.

[52]  A. Garden,et al.  Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. , 2009, International journal of radiation oncology, biology, physics.

[53]  J. Jonklaas,et al.  Outcomes of patients with differentiated thyroid carcinoma following initial therapy. , 2006, Thyroid : official journal of the American Thyroid Association.

[54]  P. Grigsby,et al.  Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma. , 2000, JAMA.

[55]  R. A’Hern,et al.  The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. , 2001, Thyroid : official journal of the American Thyroid Association.

[56]  G. Thompson,et al.  Anaplastic thyroid carcinoma: a 50-year experience at a single institution. , 2001, Surgery.

[57]  S. Larson,et al.  Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. , 2001, Thyroid : official journal of the American Thyroid Association.

[58]  E. Mazzaferri,et al.  Increasing Incidence of Thyroid Cancer in the United States, 1973–2002Davies L, Welch HG (Dept of Veterans Affairs Med Ctr, White River Junction, Vt; Darmouth Med School, Hanover, NH) JAMA 295:2164–2167, 2006§ , 2007 .

[59]  B. Cady,et al.  An expanded view of risk-group definition in differentiated thyroid carcinoma. , 1988, Surgery.

[60]  P. Lenio.  External irradiation in treatment of papillary carcinoma of the thyroid. , 1976, American journal of surgery.

[61]  R. Tsang,et al.  External beam radiation therapy for thyroid cancer. , 2008, Endocrinology and metabolism clinics of North America.

[62]  B. Prevost,et al.  Results of postoperative radiation therapy in medullary carcinoma of the thyroid: a retrospective study by the French Federation of Cancer Institutes--the Radiotherapy Cooperative Group. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[63]  S. Larson,et al.  Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. , 2009, Thyroid : official journal of the American Thyroid Association.

[64]  H. Gharib,et al.  Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. , 1985, Mayo Clinic proceedings.

[65]  C Eng,et al.  Low frequency of germline mutations in the RET proto‐oncogene in patients with apparently sporadic medullary thyroid carcinoma , 1995, Clinical endocrinology.

[66]  K. Franssila,et al.  Occult papillary carcinoma of the thyroid. A “normal” finding in finland. A systematic autopsy study , 1985, Cancer.

[67]  A. Gafni,et al.  An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. , 2008, Endocrinology and metabolism clinics of North America.

[68]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[69]  H. Gerstein,et al.  Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. , 2004, The Journal of clinical endocrinology and metabolism.

[70]  J. Tward,et al.  Surgery and Radiotherapy Improves Survival in Patients With Anaplastic Thyroid Carcinoma: Analysis of the Surveillance, Epidemiology, and End Results 1983–2002 , 2008, American journal of clinical oncology.

[71]  M. Schlumberger.  Anaplastic thyroid carcinoma. , 2005, Head & neck.

[72]  R. Huddart,et al.  Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. , 1999, Radiotherapy and Oncology.

[73]  Andrea B Troxel,et al.  Phase II trial of sorafenib in advanced thyroid cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  E. Vokes,et al.  Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  P. Grigsby,et al.  Anaplastic Thyroid Carcinoma: Comparison of Conventional Radiotherapy and Hyperfractionation Chemoradiotherapy in Two Groups , 2002, American journal of clinical oncology.

[76]  J. Franklyn,et al.  131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. , 2007, The Journal of clinical endocrinology and metabolism.

[77]  N. Reed,et al.  Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. , 1992, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[78]  T. Panzarella,et al.  Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. , 1988, International journal of radiation oncology, biology, physics.

[79]  M. Kaplan,et al.  Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. , 1990, Endocrinology and metabolism clinics of North America.

[80]  C. Hill,et al.  Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. , 1974, The New England journal of medicine.